Dopamine and the dynamics of subthalamic and leg muscle activities in parkinsonian stepping

Thomas G. Simpson,[1] Shenghong He,[1] Laura Wehmeyer,[1] Alek Pogosyan,[1] Fernando Rodriguez Plazas,[1] Ashwini Oswal,[1] Michael G. Hart,[2] Rahul S. Shah,[2] Harutomo Hasegawa,[3] Christoph Wiest,[1] Sahar Yassine,[1] Xuanjun Guo,[1] Philipp A. Loehrer,[1,6] Anca Merla,[3] Pablo Andrade,[5] Veerle Visser-Vandewalle,[5] Andrea Perera,[3] Kenneth Adindu,[3] Ahmed Raslan,[3] Andrew O'Keeffe,[3] Marie-Laure Welter,[4] Francesca Morgante,[2] Keyoumars Ashkan,[3] Erlick A. Pereira[2] and Huiling Tan[1]

Abstract

Freezing of gait (FOG) is a devastating symptom of Parkinson's disease (PD) often resulting in disabling falls and loss of independence. It affects half of patients, yet current therapeutic strategies are insufficient, and the underlying neural mechanisms remain poorly understood.

This study investigated beta oscillation dynamics in the subthalamic nucleus (STN) during different movement states (sitting, standing, and stepping), while examining the effects of levodopa. Specifically, it aimed to identify pathological activity during stepping by analysing the relationship between the STN and leg muscles and how this is modulated by levodopa. Local field potentials (LFP) in the STN and leg muscle activity measured as Electromyography (EMG) of the gastrocnemius and peroneus longus were recorded in 14 PD patients during sitting, standing, and stepping, ON and OFF levodopa.

Levodopa reduced stepping frequency variability, implying improved stepping rhythmicity. Low-beta (12-20 Hz) and high-beta (21-35 Hz) were differentially modulated by stepping movements and levodopa, with reduced high-beta and increased low-beta during stepping compared to standing and sitting. In contrast, levodopa reduced low-beta but increased high-beta activity, highlighting a potential physiological function of high-beta in the STN. Additionally, step-phase specific effects of levodopa were observed including reduced broad-beta band activity in the STN and leg muscles during the late stance and lift-off phase

1 of the contralateral leg when ON medication. Furthermore, STN beta bursts were associated

2 with increased muscle activation at movement initiation, potentially reducing the ability to

3 move freely. This study observed different effects of movement status (sitting vs. stepping

4 vs. standing) on the average amplitude of low- versus high-beta frequency bands, suggesting

5 they may serve distinct functional roles. Furthermore, there is a step-phase specific effect

6 of levodopa on STN LFPs, EMGs, and intermuscular coherence during stepping. These

7 findings offer insight for developing phase-specific stimulation strategies targeting STN beta

8 oscillations during gait.

9

10 **Author affiliations:**

11 1 Medical Research Council Brain Network Dynamics Unit, Nuffield Department of Clinical

12 Neurosciences, University of Oxford, Oxford, OX1 3TH, UK

13 2 City St George's, University of London & St George's University Hospitals NHS Foundation

14 Trust, Neuroscience & Cell Biology Research Institute, London, EC1V 0HB, UK

15 3 Department of Neurosurgery, King's College Hospital, Denmark Hill, London, SE5 9RS, UK

16 4 Department of Neurophysiology, CHU Rouen, Rouen University, 76000 Rouen, France

17 5 Department of Stereotactic and Functional Neurosurgery, University of Cologne, 50937

18 Cologne, Germany

19 6 Department of Neurology, Philipps-University Marburg, 35043 Marburg, Germany

20

21 Correspondence to: Huiling Tan

22 uffield Department of Clinical Neurosciences, University of Oxford, Level 6, West Wing,

23 John Radcliffe Hospital, Oxford, OX3 9DU, UK

24 E-mail: huiling.tan@ndcn.ox.ac.uk

25

29

1 Introduction

2 Freezing of gait (FOG) is a severely debilitating symptom of Parkinson's disease (PD) affecting
3 around 70% of patients when disease duration exceeds 10 years[1]. This symptom often leads
4 to a significant loss of independence, a reduction in quality of life, and an increased risk of
5 disabling falls. Current interventions for Parkinsonian gait generally offer limited efficacy[2,3],
6 highlighting the demand for optimised therapeutic approaches. Better understanding of the
7 neural basis of gait control in PD may offer new insight on improving the treatment of gait
8 difficulties, including FOG.

9

10 The subthalamic nucleus (STN) has a key role in gait, as it receives 'hyperdirect' inputs from
11 motor areas and serves as an important moderator of basal ganglia output[4]. It is thought to
12 regulate the integration of cortical and cerebellar information by activating or inhibiting the
13 MLR[5,6], which has an active role in initiating and modulating spinal neural circuitry for motor
14 control[7]. As the primary surgical target for deep brain stimulation (DBS) in PD, the STN has
15 been extensively studied via electrophysiological recordings and consistently shown to
16 exhibit increased oscillatory activity in the beta (13-30Hz) frequency band, which has been
17 linked to symptoms of rigidity and bradykinesia[8,9]. This overactivity can lead to excessive
18 inhibition of the MLR, disrupting the normal initiation and regulation of gait, and potentially
19 contributing to symptoms such as FOG episodes[10]. In addition, prolonged STN beta burst
20 durations during gait have been shown to differentiate freezers from non-freezers, with
21 shorter bursts observed in non-freezers[11]. Further examination of STN beta modulation
22 within the gait cycle has revealed step-phase specific fluctuations, possibly reflecting
23 variations in motor output[12].

24

25 Dopaminergic treatment with levodopa has been consistently shown to decrease beta
26 activity in subcortical structures, including the STN[13,14], while also improving objective
27 measurements of gait such as velocity, stride length, rigidity, and movement initiation[15–17].
28 However, the effect of levodopa on gait-phase related beta-band modulation in the STN
29 remains unclear. Similarly, DBS of the STN, which is known to attenuate beta activity, has
30 demonstrated efficacy in improving PD motor symptoms, including gait and FOG[18]. Recent
31 advancements in adaptive DBS based on beta activity have further shown promise in
32 ameliorating gait symptoms[19,20]. Nevertheless, the impact of DBS on gait in PD is complex,
33 with most studies reporting improvements but occasional cases observing worsened or
34 newly induced FOG[21].

35

1 Building on these insights, other studies have focused on the distinct functional roles of STN
2 activity in the low- versus high-beta frequency range[22], providing further understanding of
3 gait regulation and the pathophysiology of FOG. Low-beta activity (13-23 Hz) has been
4 reported to be modulated by levodopa and to strongly correlate with bradykinesia and
5 rigidity[22,23]. In contrast, patients with FOG exhibited higher power in the high-beta band,
6 which was significantly reduced by levodopa and associated with suppression of FOG[24].
7 Recent research also suggests that low-beta and high-beta cortico-STN coherence arises
8 through distinct networks, possibly reflecting indirect and hyperdirect pathways,
9 respectively[25,26]. Meanwhile, the beta desynchronization during lower limb movements is
10 characterised by a greater involvement of higher-beta frequencies (24-31 Hz) compared to
11 upper limb movements[27]. In addition, STN activity that is rhythmically modulated by the
12 stepping phase is also focused on the high-beta frequency range[12]. These prior findings
13 underscore the critical role of STN beta oscillations, in particular the high-beta activities in
14 gait regulation and FOG control, emphasising the need for a deeper understanding of these
15 mechanisms to optimise therapeutic strategies.

16

17 Apart from abnormal neural activities, pathological muscle activation patterns in the lower limbs
18 have also been linked to FOG[28–30]. For example, FOG is associated with a reduction in total
19 electromyography (EMG) activity in lower limb muscles, including the tibialis anterior (TA) and
20 gastrocnemius (GA), as well as shorter durations of muscle activation[28–30]. This reduction was
21 accompanied by increased amplitudes of EMG bursts in the TA, suggesting a compensation
22 strategy of pulling the leg into swing. More recent research using frequency domain analysis of
23 EMG indicates that PD freezers exhibit increased muscle activity within the alpha and low-beta
24 bands in both the TA and GA muscles compared to healthy controls during walking[31]. In addition,
25 beta bursts in the cortical motor network have been found to be associated with increased beta
26 band activity in upper limb muscles and cross-muscle phase synchrony in healthy motor
27 control[32,33]. This suggests that motor control relies on coordinated brain-muscle interactions, where
28 disruptions in such synchronization may contribute to pathological states in PD. In fact, increases
29 in pathological beta and theta rhythms in the STN have been observed to precede a temporal chain
30 of abnormal lower limb muscle firing detected by EMG[34]. Nevertheless, the precise mechanisms
31 by which abnormal brain activity translates into pathological muscle activation, and how this
32 contributes to gait impairments in PD, is poorly understood.

33

1   This study examines the dynamics of STN and EMG activities during stepping in PD, and how
2   they are modulated by dopaminergic medication. Stepping-in-place is used in this study as
3   a simplified yet functionally relevant motor behaviour that captures core elements of
4   locomotion. Stepping-in-place minimizes movement-related artifacts that often confound
5   electrophysiological recordings during free walking, allowing for more precise
6   characterization of neural activity associated with gait. Additionally, stepping-in-place can
7   be performed in constrained environments, increasing experimental control and
8   reproducibility across sessions. STN local field potential (LFP) recordings were
9   simultaneously monitored with the activity of the gastrocnemius (GA) and peroneus longus
10   (PL) muscles to investigate how abnormal neural activity translates into pathological muscle
11   activation. GA is a key muscle in stance limb stability and has been implicated in altered
12   activity and coherence patterns during FOG episodes[30,35,36]. PL, as a major mover and
13   stabilizer of the foot and ankle, acts complementary to GA during stepping, especially in the
14   stance phase[37]. This muscle selection enables investigation of muscle coupling dynamics
15   during stepping and their potential modulation by pathological brain activity. It was
16   previously shown that sensorimotor cortical beta bursts are associated with increased
17   muscle activation and intermuscular coherence in the beta frequency band[33]. Based on this
18   finding, it was hypothesized that a similar relationship might exist between subthalamic
19   nucleus (STN) beta bursts and coupling between lower limb muscles. It is further speculated
20   that elevated muscle co-activation, especially during movement phases when the muscles
21   are normally expected to act in opposition, may reflect altered or maladaptive motor control
22   strategies.

23

24   This study shows that levodopa differentially influenced low- and high-beta activities in the
25   STN during standing and stepping, providing insights into the distinct roles of beta
26   oscillations in these movement states. Furthermore, this work aims to better describe how
27   STN beta activity and lower extremity muscle activity dynamically change within the step
28   cycle and how these changes are modulated by levodopa at different stepping phases. In
29   addition, the relationship between pathological STN beta bursts and aberrant muscle
30   activation patterns during stepping is explored. The ultimate objective is to propose a step-
31   phase-specific stimulation strategy to directly target stepping and gait deficits in PD.

32

33   # Materials and methods

34

Ethical Approval

This experiment was approved by the South Central - Oxford C Research Ethics Committee.

Patients

A total of 14 patients were recruited for the study (*age = 64.5 ± 5.1 (mean ± s.d.) years, disease duration = 11 ± 6.5 (mean ± s.d.) years*). Written informed consent was obtained in line with the Declaration of the Principles of Helsinki. Patients were able to understand and complete the task, although in some cases symptoms were so debilitating, especially when OFF medication, that the paradigm could not be executed in full. In these instances, patients performed for the maximum duration possible. Recordings were conducted 4 to 7 days after the first surgery, which involved bilateral implantation of DBS electrodes in the STN (see the 'Recordings' section). Patient data, including the surgical target, age, sex assigned at birth, disease duration, and predominant symptoms, are reported in Table 1. Patient levodopa equivalent daily dose and UPDRS-III score (ON and OFF medication) are reported in Table 2.

Experimental Setup

The paradigm consisted of three separate segments: resting (sitting), standing, and stepping. In the rest condition, patients adopted a seated posture with their eyes open for 2 minutes. In the standing condition, patients alternated between 1 minute of upright posture on the force plates and 1 minute of seated posture, repeated five times for a total of 5 minutes standing. Similarly, in the stepping condition, patients alternated between stepping in place (while on the force plates) for 1 minute and seated posture for 1 minute, also repeated five times for a total of 5 minutes stepping. During the stepping-in-place condition, patients were instructed to step at a comfortable and consistent frequency, and to imagine themselves walking normally. As the focus of the study was on stepping performance rather than sit-to-stand transitions, hand support was offered to most patients during the brief transitions between seated and upright postures to ensure safety. A minute typically refers to an artefact-minimal (see the 'Stepping Phase Related Modulations' section) period of 1 minute, confirmed visually to mitigate the effect of movement artefacts. All 1-minute segments of standing and stepping included in the analysis were performed without hand support, except for one particularly frail patient who required support during stepping and standing. To synchronise behavioural conditions with the electrophysiological data, the conditions were recorded in separate files (resting, standing, and stepping). Furthermore, the movement status of the patient was interpreted from the force plates.

1

The paradigm was performed twice: once in the OFF medication state and once in the ON medication state. The OFF condition was completed in the morning, with patients' normal doses of levodopa withheld overnight. The ON condition was completed in the afternoon, with patients' normal doses of levodopa administered at midday. This enabled a direct comparison between the two states.

Recordings

The surgical target was the STN. DBS systems from two companies were implanted: Medtronic Inc. Neurological Division, USA (octopolar directional leads, SenSight™ model 33005) or Boston Scientific, USA (octopolar directional leads, Vercise™ model DB-2202). Electrodes were implanted as previously described[38], connected to temporary lead extensions and externalised through the temporal or frontal scalp. LFPs from the STN were recorded throughout the paradigm using the TMSi-SAGA amplifier (TMSi, The Netherlands), at a sampling frequency of 4096Hz. EMGs were simultaneously recorded using the same amplifier with the electrodes placed on four separate locations in bipolar configuration: *left gastrocnemius (GA$_L$), left peroneus longus (PL$_L$), right gastrocnemius (GA$_R$), right peroneus longus (PL$_R$)*. The gastrocnemius was selected due to its significant role in gait, such as influence on speed and power, propulsion, and control of important joints, with a primary role in stance limb stability[35]. Altered timing and activation patterns of the gastrocnemius have been previously implicated in freezing of gait[36]. The peroneus longus was chosen for its key role in foot and ankle stability, which is critical for propulsion, balance, and postural control[37,39]. Additionally, two force plates were recorded using the same system (recorded at the same sampling frequency) in order to capture the phase of the steps. The ground electrode was placed on the patients' wrist.

Contact Selection

Bipolar configuration was applied to LFP recordings in post-analysis to reduce activities from volume conduction and to focus on locally generated activities. Several different bipolar configurations were created post-hoc based on unipolar LFP recordings from neighbouring contacts. The combinations tested for directional leads were 1-2, 1-3, 1-4, 2-5, 3-6, 4-7, 5-8, 6-8, 7-8, while for non-directional leads 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8 were tested. Please note, a single contact was not created by combining numerous directional contacts. Instead, directional

1 and ring contacts were used individually to form bipolar configurations. From these, continuous

2 wavelet transform (CWT) was utilised to determine the amplitude spectral density (ASD) of all

3 bipolar signals from the OFF medication rest condition. The bipolar configuration with the largest

4 beta activity was selected as the configuration for use in the analysis. In 50% of the tested

5 hemispheres (14 out of 28), one of the contacts (in the bipolar configuration with the largest beta

6 amplitude) was used in the chronic stimulation configuration. The selected bipolar configuration

7 is reported in Table 2, along with the final chronic stimulation configuration.

8

9 Data Processing

10 The following analysis pipeline was implemented primarily in MATLAB (version 2019b). R
11 version 4.4.2 was used for ANOVA, and Spike2 for visualisation.

12

13 Stepping Analysis

14 Stepping frequency was defined as the number of steps completed per second. This was
15 calculated by counting the number of steps (by observing the number of times the amplitude
16 of the force plate exceeded a threshold based on the individual patients stepping force)
17 during the artefact-free part of the trial (see the 'Trial Rejection' section) and dividing this
18 value by the number of seconds. This was computed for each foot and an average stepping
19 frequency was obtained for each participant. The stepping frequency variance of each
20 participant was defined as the variability of the stepping frequency over the trial. This was
21 calculated by splitting the condition into 10 s segments and calculating a stepping frequency
22 for each segment. The standard deviation of these stepping frequencies over all segments
23 for each patient and each condition was then used to quantify variability. For analyses
24 focusing on the stepping frequency variability during the first and last parts of the condition,
25 the stepping duration of each step was recorded, and the standard deviation was calculated
26 separately for the first 20 s and the last 20 s.

27

28 LFP and EMG Analysis

29 Continuous wavelet transform (CWT) was used for time-frequency decomposition of the
30 chosen bipolar LFPs in the STN and the EMG activities from the recorded muscles. The data
31 was pre-processed with a 100 Hz low pass filter, a 1 Hz high pass filter (both second order,
32 two-pass Butterworth filters), and a 50 Hz notch filter to eliminate line noise. CWT was used
33 for time-frequency decomposition with a Morlet wavelet of 10 cycles and a standard

1 deviation of 3. The amplitude of each frequency band at different time points was calculated
2 by taking the absolute value of the complex output. The average amplitude for different
3 frequency bands and task conditions were then calculated. The amplitude of each individual
4 frequency (per 1 Hz) was z-scored over each condition (ON and OFF) for each participant
5 and then mean averaged over the period and frequency band in question. In this study, beta
6 band activity was defined within the frequency range of 12–35 Hz[40,41], with low-beta activity
7 defined as 12-20 Hz and high-beta activity defined as 21-35 Hz. This broad range is selected
8 as stepping and lower limb movements seem to be associated with modulation of activities
9 over a broader frequency band extending beyond 30 Hz[12,27,42].

10

STN Beta Burst Analysis

12 Beta bursts were defined as time periods where the average beta amplitude exceeded its
13 75th percentile for a minimum of 200 ms[43,44]. This 75th percentile was calculated for each
14 condition separately, meaning there were differing raw thresholds for bursts.

15

Intermuscular Coherence and STN-muscle Coherence

17 The phase–locking value (PLV)[45,46] was used to calculate STN-muscle coherence and
18 intermuscular coherence (IMC). This was to compute the phase consistency between the
19 STN and the lower extremity muscles, as well as the IMC between these muscles. The PLV
20 provides estimates of synchrony independent of the amplitude of oscillations. This is in
21 contrast to measures of coherence where phase and amplitude are intertwined[47]. To
22 calculate PLVs, the signals of interest were first band-pass filtered using a digital IIR filter,
23 prior to Hilbert transformation. The instantaneous phase of each signal at each time point
24 was extracted, and the phase difference between the signals were calculated. The vector
25 strength of the phase difference was computed using a sliding window technique with a fixed
26 window length of 250 ms period, with 125 ms before the sample and 125 ms after. The value
27 at each time point is the vector strength of the phase difference over this 250 ms window.
28 This was computed over the entire duration of the condition under analysis. This procedure
29 was repeated for each frequency band to generate a time-frequency coherence plot. The
30 mean was found for each patient, before finally computing the mean across all patients.

31

32 For STN-muscle coherence, the STN signal was kept the same and the EMG data was
33 randomly shuffled to generate a comparison which was subtracted from the original to give
34 the difference between the observed data and the shuffled data. This eliminates the

9

influence of one signal and focuses on the coherence between the two of them.

Stepping Phase Related Modulations

To analyse the stepping phase related changes in the STN LFPs, EMG activities, as well as the STN-muscle connectivity and IMC, the time-series of the recorded stepping force of each foot was first Hilbert transformed to find the phase of the step, from $-\pi/2$ to $\pi/2$ radians. Each step cycle was then divided into 181 different bins according to the calculated phase. The average amplitude of STN LFP activities, muscle EMG activities, STN-muscle connectivity, and IMC in different frequency band were found for each phase bin. These were z-scored for each participant, by condition (ON and OFF), as described in the 'LFP and EMG Analysis' section. This result was then averaged over all patients, allowing for analysis of electrophysiological modulation according to stepping phase.

Trial Rejection

Prior to processing in MATLAB, the raw recorded data was loaded into Spike2 for visualisation. Obvious artefacts were identified and only data considered as clean was selected for inclusion in the analysis. Artefacts include ocular, jaw clenching, or mechanically induced (from the cable movement) disturbances on the salient channels for the analysis, particularly the STN LFPs and EMG data. In addition, clearly identifiable stepping induced force readings from the plates was also required to define data from that step as clean. This procedure resulted in an average of 14.22% ± 21.98% of data excluded ON medication, and 15.66% ± 23.31% excluded OFF medication, with the value for each patient given in Table 1.

Statistics

Due to the small sample sizes available, non-parametric tests were used to increase the robustness of the results. When analysing the effects of two or more experimental conditions (for example medication, frequency band, and movement status) a non-parametric approach was used by preprocessing the data with the Aligned Rank Transform before applying a repeated measures ANOVA. The Wilcoxon Signed Rank test was used for post-hoc testing, and when there was only one experimental condition with two groups.

Furthermore, permutation-based cluster analysis was utilised to test whether the EMG

1 amplitude, STN-muscle coherence, and IMC in different frequency bands during stepping
2 were significantly different between ON and OFF levodopa medication, or between beta
3 bursts and no bursts. This was implemented by generating a paired *t*-test plot between the
4 two conditions. *T*-statistics for the clusters were then determined, as well as the sizes of the
5 clusters in pixels, with the largest values selected as the largest cluster. Then, the null
6 distribution was generated by randomly swapping the pairings in the paired samples *t*-test,
7 where the largest *t*-statistic and cluster size were recorded for each permutation, which
8 created a set of possible cluster sizes under the null hypothesis. Finally, two p-values were
9 generated, one for the cluster size and one for the accumulated *t*-statistic, computed by
10 comparison with the null distribution. Only the overall *p*-value from the accumulated *t*-
11 statistic method is reported here, because there were no results that changed between the
12 two methods.

13

Results

Levodopa decreases variance of patient stepping frequency

16 To evaluate behavioural changes induced by medication, analyses were conducted on
17 patient stepping patterns (i.e. stepping frequency and its variability). Results indicated that
18 there was a borderline significant effect of medication on the stepping frequency, with a
19 marginal increase in the frequency when ON medication ($Z = -1.73, p = .084$; **Fig. 1B**).
20 Furthermore, an analysis of the variability (standard deviation) of stepping frequency
21 revealed a statistically significant difference between conditions ($Z = 2.29, p = .022$; **Fig. 1A**),
22 with reduced variability in stepping frequency when ON medication.

23

24 A two-way ANOVA was conducted to evaluate the effects of medication (ON vs. OFF) and
25 time-related changes on stepping frequency and its variability, focusing on the initial versus
26 final 20 s intervals of stepping. This tested whether the overall increase in step frequency
27 variability when OFF medication was due to changes over time. This analysis showed that
28 medication had a significant effect on stepping frequency ($F(1, 39) = 4.18, p = .048$),
29 increasing it on average. It also showed a statistically significant effect of the time interval
30 ($F(1, 39) = 7.70, p = .008$), with stepping frequency increasing in the final 20 s. For variability,
31 there was an effect of medication on the standard deviation of stepping frequency in the
32 initial and final 20 s of stepping ($F(1, 39) = 5.55, p = .024$). However, the time interval did not
33 affect the stepping frequency standard deviation ($F(1, 39) = 0.63, p = .43$) and no interaction
34 effect was observed with medication ($F(1, 39) = 0.18, p = .67$). This implied that the variability

11

1 in stepping frequency was not due to time-related changes (such as slowing down or
2 speeding up).

3

Different effects of levodopa and locomotor status on low- vs. high-beta band activities in the STN LFPs

6 Initial analysis examined the effects of medication on the amplitude spectral density (ASD)
7 of STN LFPs recorded during sitting, standing, and stepping, using a permutation cluster
8 analysis, with results presented in **Fig. 1C-E**. The ASD was computed for frequencies ranging
9 from 10 – 100 Hz and normalised by dividing each value by the area under the curve. The
10 cluster-based permutation test showed that medication reduced activities in the low-beta
11 frequency band across all different movement states, even though the exact frequency band
12 is slightly different (Fig. 1C-E). During resting, this analysis revealed significant reduction in
13 the activities between 14-16 Hz with medication. During stepping, this analysis revealed a
14 significant reduction in the 17-21 Hz band ($t = 2.66, p = .011$), as well as an increase in 28-34
15 Hz activity ($t = -2.30, p = .017$) when ON medication compared with OFF medication. During
16 standing, levodopa medication also decreased the activity in the 12-18 Hz band ($t = 3.92, p
17 < .001$) while increasing activity in 39-49 Hz ($t = -3.46, p < .001$).

18

19 Subsequently, a three-way ANOVA was conducted on the beta amplitude with main factors
20 of medication (ON vs. OFF), movement status (sitting vs. stepping vs. standing), and sub-
21 beta frequency band (high (21-35 Hz) vs. low (12-20 Hz)) with the frequency ranges frequently
22 used in previous publications. This analysis revealed that there were significant main effects
23 of medication ($F(1, 297) = 4.39, p = .037$), movement status ($F(2, 297) = 4.85, p = .008$), and
24 beta frequency band ($F(1, 297) = 111.14, p < .0001$), on the different sub-beta amplitudes.
25 There was a significant interaction between medication and beta frequency band ($F(1, 297)
26 = 13.14, p = .0003$), and a significant interaction between movement status and beta
27 frequency band ($F(2, 297) = 26.79, p < .0001$). However, there was no interaction between
28 medication and movement status ($F(2, 297) = 0.14, p = .87$), nor three-way interaction
29 between medication, movement status, and beta frequency band ($F(2, 297) = 0.11, p = .90$).

30

31 Further non-parametric ranked tests applied to data collapsed across medication status
32 were used to explore the 2-way interaction between the locomotion status and the sub-beta
33 frequency bands (**Fig. 2A and B**). For high-beta, this showed that there was a significant
34 difference between sitting and standing ($Z = 3.80, p = 0.0001$), sitting and stepping ($Z = 4.12,$

12

1 *p < 0.0001*), and between standing and stepping (*Z = 4.01, p < 0.0001*). Additionally, for low-
2 beta, there was no significant difference between sitting and standing (*Z = 0.75, p = 0.45*),
3 but there was between sitting and stepping (*Z = -3.39, p = 0.0006*), and standing and stepping
4 (*Z = -4.01, p < 0.0001*). Overall, stepping was associated with the highest low-beta band
5 activities and the lowest high-beta activities compared to standing and sitting. The results
6 were corrected for multiple comparisons utilising the Bonferroni correction with a
7 significance threshold of 0.05 divided by 6 (0.008).

8

9 Non-parametric ranked test applied to data collapsed across locomotion status was used
10 to further explore the significant 2-way interaction between medication and sub-beta
11 frequency bands (**Fig. 2C and D**). This revealed significant differences for low-beta (Z = -2.98,
12 p = 0.003), and for high-beta (Z = 2.28, p = 0.023), where medication reduced the activities in
13 the low-beta frequency bands and increased the activities in the high-beta frequency band,
14 when considering all data averaged across different movement states. The post-hoc tests
15 utilise the Bonferroni correction for multiple comparisons with a significance threshold of
16 0.05 divided by 2 (0.025).

17

18 Reduced beta-band activity around the contralateral late stance and lift-
19 off phase when ON levodopa

20 To explore the effect of stepping phase on STN and EMG activity, and whether medication
21 induced phase-specific changes, force plate readings were used to extract the step phase,
22 as detailed in the 'Stepping Analysis' section **(Fig. 3A)**. Consistent with previous findings[12],
23 step-phase related modulation of beta band activities in the STN LFPs were observed. These
24 modulations mirrored contralateral muscle activity both ON and OFF medication (**Fig. 3D,
25 E, H, I, L, and M)**, with beta band activities in the STN LFPs increasing and decreasing in sync
26 with muscle activities in the contralateral leg. One-dimensional permutation cluster
27 analysis demonstrated a significant difference in STN beta activity (12-35 Hz) from 0 to $\pi/4$
28 (the late stance phase after peak stepping force) between OFF and ON medication states (*t
29 = 2.299, p = .018*, **Fig. 3B**). This phase corresponds to weight-shifting and movement
30 initiation (lift-off) stages of the gait cycle, where beta activity is generally reduced. This beta
31 reduction was more pronounced in the ON medication state, indicating a stronger
32 suppression of beta activity during the contralateral late stance and lift-off phase compared
33 to the OFF medication state. The same analysis was then conducted for the EMG activity,
34 which revealed a clear increase in muscle activity during the same 0 to $\pi/4$ phase in both
35 muscles (*gastrocnemius: p = .030, peroneus longus: .043*) when OFF medication compared

13

with ON medication (**Fig. 3J, K, N, O**). While this increase of activity was observed across beta and into the gamma range, the exaggerated beta activity was consistent across muscles and particularly prominent in the gastrocnemius.

Increased beta-band STN-muscle and intermuscular coherence during late stance phase

Further analysis examined STN-muscle coherence and intermuscular coherence (IMC between the gastrocnemius-peroneus longus coherence of the same leg) in relation to the stepping phase. The step-phase related modulation pattern of the IMC (**Fig. 4B and C**) showed an opposite pattern compared to the muscle amplitude modulation pattern (**Fig. 3H, I, L, and M**). The STN-muscle coherence and IMC in the alpha/beta bands increased from phase 0 to $\pi/4$ (i.e. the late stance and lift-off phase), while amplitudes of STN and muscle activities decreased relative to phases in the step cycle. Permutation cluster analysis revealed a significant increase in IMC in the beta band (*p = .020*) between 0 and $\pi/4$ when ON medication compared to OFF (**Fig. 4A**). This indicates that when OFF levodopa, there was reduced phase synchrony between the gastrocnemius and peroneus longus muscles in the same leg during late stance and lift-off phase compared to ON medication, despite the overall increase in muscle activity in the same time window.

STN beta bursts are linked to increased beta band activities in the EMG

Beta bursting activity was extracted according to the procedure outlined in the 'STN Beta Burst Analysis' section. In addition, the amplitude by frequency of the EMG was computed over the entire recording. Then, EMG activity corresponding to STN beta burst onset was extracted. Due to the previous finding showing phase-locked increases in EMG activity during a specific phase of the stepping cycle, only STN bursts occurring between 0 and $\pi/4$ radians were considered, presented in **Fig. 5A and B**. A permutation cluster analysis revealed a significant increase in EMG beta band amplitudes around STN beta burst onset between OFF and ON medication for both the gastrocnemius (*p = .020*; **Fig. 5**) and the peroneus longus (*p = .040*; **Fig. 5D)**.

Discussion

This study provides key insights into the role of beta oscillations during stepping in PD and

14

the modulatory effects of levodopa. Firstly, levodopa medication and movement status were found to have opposing effects on low- versus high-beta activity, indicating different roles of these beta sub-bands in motor control in PD. Secondly, a step-phase specific effect of levodopa on beta oscillations during stepping was observed, with significantly decreased beta activity in the STN, the gastrocnemius, and the peroneus longus muscles during the late stance and lift-off phase when ON levodopa medication. Lastly, STN beta bursts during this stepping phase were associated with increased beta activity in the EMGs in the gastrocnemius and peroneus longus muscles. Increased beta activity in the STN and lower extremity muscles may be associated with reduced movement efficiency, increased exertion, and impaired motor coordination. Together, these findings emphasise the importance of phase-specific beta modulation and its relationship with muscle activation, providing a potential rationale for targeted phase-based stimulation strategies to address gait impairments in PD.

Different effects of movement status on average amplitude of low- vs. high-beta frequency bands

The results demonstrate opposing effects of movement status (stepping vs. standing and stepping vs. resting) on the average amplitude of low- versus high- beta frequency bands in the STN. Specifically, stepping was associated with increased low-beta and reduced high-beta activity compared with standing and resting, independent of medication status. Suppression of high-beta might be necessary during stepping to facilitate active alternating movements, such as lifting, swinging, and lift-off. This is consistent with a previous study showing that lower limb movements were associated with greater desynchronization in the high-beta frequency bands (24–31 Hz) compared to low-beta band or upper limb movements[27]. Meanwhile, an earlier study has shown that PD patients with FOG exhibited elevated high-beta power compared to those without FOG, with significant reductions in high-beta power following levodopa administration along with suppression of FOG[24].

The present findings also reveal different effects of levodopa on low- versus high-beta frequency bands in the STN. When averaged across all movement states (resting, standing, and stepping), levodopa reduced the amplitude of low-beta frequency band oscillations while increasing high-beta oscillations. The reduction in low-beta activity is consistent with previous findings[8,48,49], highlighting its pathological nature. On the other hand, the increase in high-beta activity suggests a potential physiological function of this frequency band during resting, standing, and stepping. Recent research supports the notion that supplementary

1   motor area activity selectively drives high-beta STN activity via the hyperdirect pathway,

2   suggesting a functional role for high-beta frequencies in cortico-subcortical

3   communication[26]. Furthermore, low- versus high-beta band cortico-subcortical coherence

4   have been implicated to play different roles in movement inhibition and expectation[50].

5

6   It should be recognised that most patients in this study were tremor dominant or exhibited

7   main symptoms of bradykinesia and rigidity, hence, comparisons between patients with and

8   without FOG were not feasible. Future studies focusing on patients with FOG may further

9   elucidate the pathophysiological role of low- versus high-beta in gait impairment in PD.

10

Step-phase specific effect of levodopa on STN LFPs, EMGs, and intermuscular coherence during stepping

13   Consistent with previous findings, beta band activity in the STN exhibited step-phase related

14   modulation, increasing during the early stance phase and decreasing during the late stance

15   phase and lift-off of the contralateral leg. This reduction in beta activity during the late stance

16   and lift-off phase may be linked to movement initiation[12,51,52]. Yet, the role of muscle activity

17   during stepping is less understood. In the present study, medication increased the

18   intermuscular coherence during the late stance and lift-off phase, despite a reduction in

19   total amplitude of muscle activity, which may indicate more effective coordination between

20   the recorded muscles during movement initiation. This is consistent with a previous study

21   showing that patients with PD exhibited reduced intermuscular zero-lag coherence in the

22   beta/gamma frequency band during end-of-stance phase[53].

23

24   In addition, a step-phase specific effect of levodopa on STN LFPs, EMGs and intermuscular

25   coherence during stepping was observed, which was constrained to the late stance and lift-

26   off phase. When OFF medication, there was an increase of STN beta activity and EMG

27   activities, as well as reduced intermuscular coherence in the effected phase. Increased STN

28   beta activity during this phase window may be associated with delayed movement initiation

29   and reduced movement speed[54–56]. On the other hand, increased EMG activities in both the

30   gastrocnemius and peroneus longus were observed, but with a reduction of intermuscular

31   coherence (phase synchrony) in the beta frequency band. The reduction in STN beta activity

32   appears to precede changes in EMG activity (**Fig. 3A**), suggesting a causal relationship where

33   STN activity influences muscle activation. This is further supported by the observed effect of

34   beta bursts on EMG activity, which revealed an increase in muscle activation following

16

heightened beta activity in the STN, similar to previous observations of cortical beta bursts[32,33]. Conversely, reduction of STN beta activity could enable the muscle to release from a tonic state and transition more smoothly into the step phase.

Although the increase in muscle activity resulting from STN beta bursts may initially seem minor, it may have significant consequences for gait. One possible outcome is a reduction of movement efficiency, requiring greater effort to complete the same movement[57]. This could result in faster depletion of energy levels[58], further slowing movement and impairing motor coordination. Increased muscle activity may also inhibit natural stepping motion, which may result in compensatory mechanisms and strategies that are suboptimal[59], such as recruitment of other muscle groups which could also reduce energy levels[60]. Furthermore, this increase of muscle activity with reduced intermuscular coherence indicates altered muscle activation patterns, which are both linked to altered timing of the gait cycle[61]. In turn, this alteration of timing has been proposed as a possible contributor to FOG[30]. Similarly, the inability of patients to effectively produce muscle coordination at movement initiation may also contribute to stepping disturbance. This could result in a number of consequences, including an increase in effort to execute the movement, prompting of compensatory mechanisms, and higher levels of fatigue.

Implications for Future Stimulation Strategies

There are several implications for future stimulation strategies that emanate from this work. The results suggest that during parkinsonian stepping the motor outputs (both beta band activities in the STN LFPs and EMG activities in the lower extremity) were significantly affected from phases 0 to $\pi/4$ in each step cycle, which correspond to the late stance and lift-off phase. This supports the view that stimulating between 0 and $\pi/4$, utilising a stepping-based phase-triggered stimulation strategy, could further probe the causal relationship between the observed increase in STN beta band activity and gait impairment in PD. It may also offer beneficial effects for patients during stepping and potentially free walking. Additionally, it could reduce variations of timing in the gait cycle, alleviating one of the contributing factors to freezing of gait, thereby potentially reducing these episodes. Another possible ramification is a reduction in reliance on compensatory mechanisms.

Limitations and Future Work

A primary limitation of this work, due to the challenge of recruiting patients with externalised

17

leads, is the limited sample size. Another limitation is that stepping-in-place was recorded for this study in order to minimise movement-related artefacts in the LFP and EMG recordings. Stepping-in-place is different from free walking, for instance, there is no forward momentum during stepping-in-place (which is crucial for walking). Moreover, the stepping-in-place task involves vertical up and down leg movements while maintaining balance rather than propelling the body forward as during walking. Some participants reported that stepping-in-place is less fluid or automatic than walking. Therefore, attributing the present effects directly to free walking should be approached cautiously, although a previous study showed similar pattern of STN beta-band modulation aligned to the stepping phase within each step cycle during free walking in a few patients[12]. Moreover, analyses in this study focused on steps that could be reliably detected using force plate measurements and did not include episodes of hastening or true freezing. Whether the observed increases in STN beta activity and intermuscular coherence during the late stance phase when OFF levodopa are associated with poor motor performance during free walking remains to be tested in future studies. Additionally, while the gastrocnemius and peroneus longus were selected in this study for their known roles in stance stability and foot control, simultaneous monitoring of multiple muscles in future studies, especially multiple antagonistic muscle pairs, such as the gastrocnemius and tibialis anterior may offer more insight on the pathophysiology of free walking. Finally, the timing of experimental sessions may represent a confound, as the OFF medication sessions are recorded in the morning and the ON medication sessions in the afternoon, and stepping was recorded after standing in both medication conditions. Patients may have experienced reduced energy and motivation later in the day, potentially affecting performance.

Future work could focus on STN activity around periods that can instigate freezing episodes for example, stopping, turning, or moving through a doorway. Furthermore, studies testing different stimulation strategies at different phases of stepping are critical to evaluate the efficacy of the proposed approach, with testing in real-world gait scenarios a prerequisite for clinical translation.

Data availability

All data will be shared on the MRC BNDU Data Sharing Platform (https://data.mrc.ox.ac.uk/)

upon publication.

Funding

Competing interests

The authors declare no competing interests.

Supplementary material

Supplementary material is available at *Brain* online.

References

[1] Ge HL, Chen XY, Lin YX, Ge TJ, Yu LH, Lin ZY, et al. The prevalence of freezing of gait in Parkinson's disease and in patients with different disease durations and severities. *Chin Neurosurg J*. 2020;6(1):17. doi:10.1186/s41016-020-00197-y

[2] Smith MD, Brazier DE, Henderson EJ. Current Perspectives on the Assessment and Management of Gait Disorders in Parkinson's Disease. *Neuropsychiatr Dis Treat*. 2021;17:2965-2985. doi:10.2147/ndt.s304567

[3] Müller MLTM, Marusic U, Boas M van E, Weiss D, Bohnen NI. Treatment options for

postural instability and gait difficulties in Parkinson's disease. *Expert Rev Neurother*. 2019;19(12):1229-1251. doi:10.1080/14737175.2019.1656067

[4] Hamani C, Saint-Cyr JA, Fraser J, Kaplitt M, Lozano AM. The subthalamic nucleus in the context of movement disorders. *Brain*. 2004;127(1):4-20. doi:10.1093/brain/awh029

[5] Arnulfo G, Pozzi NG, Palmisano C, Leporini A, Canessa A, Brumberg J, et al. Phase matters: A role for the subthalamic network during gait. *PLoS ONE*. 2018;13(6):e0198691. doi:10.1371/journal.pone.0198691

[6] Takakusaki K. Forebrain control of locomotor behaviors. *Brain Res Rev*. 2008;57(1):192-198. doi:10.1016/j.brainresrev.2007.06.024

[7] Takakusaki K. Functional Neuroanatomy for Posture and Gait Control. *J Mov Disord*. 2017;10(1):1-17. doi:10.14802/jmd.16062

[8] Little S, Brown P. The functional role of beta oscillations in Parkinson's disease. *Parkinsonism Relat D*. 2014;20:S44-S48. doi:10.1016/s1353-8020(13)70013-0

[9] Brown P. Abnormal oscillatory synchronisation in the motor system leads to impaired movement. *Curr Opin Neurobiol*. 2007;17(6):656-664. doi:10.1016/j.conb.2007.12.001

[10] Mirelman A, Bonato P, Camicioli R, Ellis TD, Giladi N, Hamilton JL, et al. Gait impairments in Parkinson's disease. *Lancet Neurol*. 2019;18(7):697-708. doi:10.1016/s1474-4422(19)30044-4

[11] Anidi C, O'Day JJ, Anderson RW, Afzal MF, Syrkin-Nikolau J, Velisar A, et al. Neuromodulation targets pathological not physiological beta bursts during gait in Parkinson's disease. *Neurobiol Dis*. 2018;120:107-117. doi:10.1016/j.nbd.2018.09.004

[12] Fischer P, Chen CC, Chang YJ, Yeh CH, Pogosyan A, Herz DM, et al. Alternating Modulation of Subthalamic Nucleus Beta Oscillations during Stepping. *J Neurosci*. 2018;38(22):5111-5121. doi:10.1523/jneurosci.3596-17.2018

[13] Kühn AA, Kupsch A, Schneider G, Brown P. Reduction in subthalamic 8–35 Hz oscillatory activity correlates with clinical improvement in Parkinson's disease. *Eur J Neurosci*. 2006;23(7):1956-1960. doi:10.1111/j.1460-9568.2006.04717.x

[14] Kühn AA, Tsui A, Aziz T, Ray N, Brücke C, Kupsch A, et al. Pathological synchronisation

in the subthalamic nucleus of patients with Parkinson's disease relates to both bradykinesia and rigidity. *Exp Neurol*. 2009;215(2):380-387. doi:10.1016/j.expneurol.2008.11.008

[15] Gao L, Zhang J, Chan P, Wu T. Levodopa Effect on Basal Ganglia Motor Circuit in Parkinson's Disease. *CNS Neurosci Ther*. 2017;23(1):76-86. doi:10.1111/cns.12634

[16] Prochazka A, Bennett DJ, Stephens MJ, Patrick SK, Sears-Duru R, Roberts T, et al. Measurement of rigidity in Parkinson's disease. *Mov Disord*. 1997;12(1):24-32. doi:10.1002/mds.870120106

[17] Lubik S, Fogel W, Tronnier V, Krause M, König J, Jost WH. Gait analysis in patients with advanced Parkinson disease: different or additive effects on gait induced by levodopa and chronic STN stimulation. *J Neural Transm*. 2006;113(2):163-173. doi:10.1007/s00702-005-0310-8

[18] Karachi C, Cormier-Dequaire F, Grabli D, Lau B, Belaid H, Navarro S, et al. Clinical and anatomical predictors for freezing of gait and falls after subthalamic deep brain stimulation in Parkinson's disease patients. *Park Relat Disord*. 2019;62:91-97. doi:10.1016/j.parkreldis.2019.01.021

[19] Wilkins KB, Petrucci MN, Lambert EF, Melbourne JA, Gala AS, Akella P, et al. Beta Burst-Driven Adaptive Deep Brain Stimulation Improves Gait Impairment and Freezing of Gait in Parkinson's Disease. *medRxiv*. Published online 2024:2024.06.26.24309418. doi:10.1101/2024.06.26.24309418

[20] Isaias IU, Caffi L, Borellini L, Ampollini AM, Locatelli M, Pezzoli G, et al. Case report: Improvement of gait with adaptive deep brain stimulation in a patient with Parkinson's disease. *Front Bioeng Biotechnol*. 2024;12:1428189. doi:10.3389/fbioe.2024.1428189

[21] Gao C, Liu J, Tan Y, Chen S. Freezing of gait in Parkinson's disease: pathophysiology, risk factors and treatments. *Transl Neurodegener*. 2020;9(1):12. doi:10.1186/s40035-020-00191-5

[22] Priori A, Foffani G, Pesenti A, Tamma F, Bianchi AM, Pellegrini M, et al. Rhythm-specific pharmacological modulation of subthalamic activity in Parkinson's disease. *Exp Neurol*. 2004;189(2):369-379. doi:10.1016/j.expneurol.2004.06.001

[23] Wijk BCM van, Beudel M, Jha A, Oswal A, Foltynie T, Hariz MI, et al. Subthalamic nucleus phase–amplitude coupling correlates with motor impairment in Parkinson's disease. *Clin*

1 *Neurophysiol*. 2016;127(4):2010-2019. doi:10.1016/j.clinph.2016.01.015

2 [24] Toledo JB, López-Azcárate J, Garcia-Garcia D, Guridi J, Valencia M, Artieda J, et al. High

3 beta activity in the subthalamic nucleus and freezing of gait in Parkinson's disease. *Neurobiol*

4 *Dis*. 2014;64:60-65. doi:10.1016/j.nbd.2013.12.005

5 [25] Oswal A, Beudel M, Zrinzo L, Limousin P, Hariz M, Foltynie T, et al. Deep brain

6 stimulation modulates synchrony within spatially and spectrally distinct resting state networks in

7 Parkinson's disease. *Brain*. 2016;139(5):1482-1496. doi:10.1093/brain/aww048

8 [26] Oswal A, Cao C, Yeh CH, Neumann WJ, Gratwicke J, Akram H, et al. Neural signatures of

9 hyperdirect pathway activity in Parkinson's disease. *Nat Commun*. 2021;12(1):5185.

10 doi:10.1038/s41467-021-25366-0

11 [27] Tinkhauser G, Shah SA, Fischer P, Peterman K, Debove I, Nygyuen K, et al.

12 Electrophysiological differences between upper and lower limb movements in the human

13 subthalamic nucleus. *Clin Neurophysiol*. 2019;130(5):727-738. doi:10.1016/j.clinph.2019.02.011

14 [28] Cantú H, Nantel J, Millán M, Paquette C, Côté JN. Abnormal Muscle Activity and

15 Variability Before, During, and After the Occurrence of Freezing in Parkinson's Disease. *Front*

16 *Neurol*. 2019;10:951. doi:10.3389/fneur.2019.00951

17 [29] Caliandro P, Ferrarin M, Cioni M, Bentivoglio AR, Minciotti I, D'Urso PI, et al. Levodopa

18 effect on electromyographic activation patterns of tibialis anterior muscle during walking in

19 Parkinson's disease. *Gait Posture*. 2011;33(3):436-441. doi:10.1016/j.gaitpost.2010.12.020

20 [30] Nieuwboer A, Dom R, Weerdt WD, Desloovere K, Janssens L, Stijn V. Electromyographic

21 profiles of gait prior to onset of freezing episodes in patients with Parkinson's disease. *Brain*.

22 2004;127(7):1650-1660. doi:10.1093/brain/awh189

23 [31] Breu MS, Schneider M, Klemt J, Cebi I, Gharabaghi A, Weiss D. People With Parkinson's

24 Disease and Freezing of Gait Show Abnormal Low Frequency Activity of Antagonistic Leg

25 Muscles. *Front Hum Neurosci*. 2022;15:733067. doi:10.3389/fnhum.2021.733067

26 [32] Echeverria-Altuna I, Quinn AJ, Zokaei N, Woolrich MW, Nobre AC, Ede F van. Transient

27 beta activity and cortico-muscular connectivity during sustained motor behaviour. *Prog*

28 *Neurobiol*. 2022;214:102281. doi:10.1016/j.pneurobio.2022.102281

1 [33] Simpson TG, Godfrey W, Torrecillos F, He S, Herz DM, Oswal A, et al. Cortical beta

2 oscillations help synchronise muscles during static posture holding in healthy motor control.

3 *NeuroImage*. 2024;298:120774. doi:10.1016/j.neuroimage.2024.120774

4 [34] Georgiades MJ, Shine JM, Gilat M, McMaster J, Owler B, Mahant N, et al. Hitting the

5 brakes: pathological subthalamic nucleus activity in Parkinson's disease gait freezing. *Brain*.

6 2019;142(12):3906-3916. doi:10.1093/brain/awz325

7 [35] Jonkers I, Stewart C, Spaepen A. The complementary role of the plantarflexors, hamstrings

8 and gluteus maximus in the control of stance limb stability during gait. *Gait Posture*.

9 2003;17(3):264-272. doi:10.1016/s0966-6362(02)00102-9

10 [36] Klocke P, Loeffler MA, Muessler H, Breu MS, Gharabaghi A, Weiss D. Supraspinal

11 contributions to defective antagonistic inhibition and freezing of gait in Parkinson's disease.

12 *Brain*. 2024;147(12):4056-4071. doi:10.1093/brain/awae223

13 [37] Louwerens JWK, Linge B van, Klerk LWL de, Mulder PGH, Snijders CJ. Peroneus longus

14 and tibialis anterior muscle activity in the stance phase: A quantified electromyographic study of

15 10 controls and 25 patients with chronic ankle instability. *Acta Orthop Scand*. 2009;66(6):517-

16 523. doi:10.3109/17453679509002306

17 [38] Wiest C, He S, Duchet B, Pogosyan A, Benjaber M, Denison T, et al. Evoked resonant

18 neural activity in subthalamic local field potentials reflects basal ganglia network dynamics.

19 *Neurobiol Dis*. 2023;178:106019. doi:10.1016/j.nbd.2023.106019

20 [39] Bellew JW, Dunn S. Ankle Rehabilitation: A Reintroduction of the Peroneus Longus.

21 *Strength Cond J*. 2002;24(4):61. doi:10.1519/00126548-200208000-00017

22 [40] Moran RJ, Mallet N, Litvak V, Dolan RJ, Magill PJ, Friston KJ, et al. Alterations in Brain

23 Connectivity Underlying Beta Oscillations in Parkinsonism. *PLoS Comput Biol*.

24 2011;7(8):e1002124. doi:10.1371/journal.pcbi.1002124

25 [41] Jurewicz K, Paluch K, Kublik E, Rogala J, Mikicin M, Wróbel A. EEG-neurofeedback

26 training of beta band (12–22 Hz) affects alpha and beta frequencies – A controlled study of a

27 healthy population. *Neuropsychologia*. 2018;108:13-24.

28 doi:10.1016/j.neuropsychologia.2017.11.021

29 [42] Thenaisie Y, Lee K, Moerman C, Scafa S, Gálvez A, Pirondini E, et al. Principles of gait

encoding in the subthalamic nucleus of people with Parkinson's disease. *Sci Transl Med*. 2022;14(661):eabo1800. doi:10.1126/scitranslmed.abo1800

[43] Tinkhauser G, Torrecillos F, Duclos Y, Tan H, Pogosyan A, Fischer P, et al. Beta burst coupling across the motor circuit in Parkinson's disease. *Neurobiol Dis*. 2018;117:217-225. doi:10.1016/j.nbd.2018.06.007

[44] Tinkhauser G, Pogosyan A, Tan H, Herz DM, Kühn AA, Brown P. Beta burst dynamics in Parkinson's disease OFF and ON dopaminergic medication. *Brain*. 2017;140(11):2968-2981. doi:10.1093/brain/awx252

[45] Aydore S, Pantazis D, Leahy RM. A note on the phase locking value and its properties. *NeuroImage*. 2013;74:231-244. doi:10.1016/j.neuroimage.2013.02.008

[46] Celka P. Statistical Analysis of the Phase-Locking Value. *IEEE Signal Process Lett*. 2007;14(9):577-580. doi:10.1109/lsp.2007.896142

[47] Uhlhaas PJ, Roux F, Rodriguez E, Rotarska-Jagiela A, Singer W. Neural synchrony and the development of cortical networks. *Trends Cogn Sci*. 2010;14(2):72-80. doi:10.1016/j.tics.2009.12.002

[48] Jenkinson N, Brown P. New insights into the relationship between dopamine, beta oscillations and motor function. *Trends Neurosci*. 2011;34(12):611-618. doi:10.1016/j.tins.2011.09.003

[49] Giannicola G, Marceglia S, Rossi L, Mrakic-Sposta S, Rampini P, Tamma F, et al. The effects of levodopa and ongoing deep brain stimulation on subthalamic beta oscillations in Parkinson's disease. *Exp Neurol*. 2010;226(1):120-127. doi:10.1016/j.expneurol.2010.08.011

[50] Cao C, Litvak V, Zhan S, Liu W, Zhang C, Sun B, et al. Low-beta versus high-beta band cortico-subcortical coherence in movement inhibition and expectation. *Neurobiol Dis*. 2024;201:106689. doi:10.1016/j.nbd.2024.106689

[51] Crenna P, Carpinella I, Rabuffetti M, Rizzone M, Lopiano L, Lanotte M, et al. Impact of subthalamic nucleus stimulation on the initiation of gait in Parkinson's disease. *Exp Brain Res*. 2006;172(4):519-532. doi:10.1007/s00221-006-0360-7

[52] Kojovic M, Higgins A, Jahanshahi M. In Parkinson's disease STN stimulation enhances

24

responsiveness of movement initiation speed to high reward value. *Neuropsychologia*. 2016;89:273-280. doi:10.1016/j.neuropsychologia.2016.06.033

[53] Weersink JB, Jong BM de, Maurits NM. Neural coupling between upper and lower limb muscles in Parkinsonian gait. *Clin Neurophysiol*. 2022;134:65-72. doi:10.1016/j.clinph.2021.11.072

[54] Torrecillos F, Tinkhauser G, Fischer P, Green AL, Aziz TZ, Foltynie T, et al. Modulation of Beta Bursts in the Subthalamic Nucleus Predicts Motor Performance. *J Neurosci*. 2018;38(41):8905-8917. doi:10.1523/jneurosci.1314-18.2018

[55] He S, Mostofi A, Syed E, Torrecillos F, Tinkhauser G, Fischer P, et al. Subthalamic beta-targeted neurofeedback speeds up movement initiation but increases tremor in Parkinsonian patients. *eLife*. 2020;9:e60979. doi:10.7554/elife.60979

[56] Lofredi R, Tan H, Neumann WJ, Yeh CH, Schneider GH, Kühn AA, et al. Beta bursts during continuous movements accompany the velocity decrement in Parkinson's disease patients. *Neurobiol Dis*. 2019;127:462-471. doi:10.1016/j.nbd.2019.03.013

[57] Graham RB, Wachowiak MP, Gurd BJ. The Assessment of Muscular Effort, Fatigue, and Physiological Adaptation Using EMG and Wavelet Analysis. *PLoS ONE*. 2015;10(8):e0135069. doi:10.1371/journal.pone.0135069

[58] Hagell P, Brundin L. Towards an understanding of fatigue in Parkinson disease. *J Neurol, Neurosurg Psychiatry*. 2009;80(5):489. doi:10.1136/jnnp.2008.159772

[59] Nonnekes J, Růžička E, Nieuwboer A, Hallett M, Fasano A, Bloem BR. Compensation Strategies for Gait Impairments in Parkinson Disease. *JAMA Neurol*. 2019;76(6):718-725. doi:10.1001/jamaneurol.2019.0033

[60] Fletcher JR, MacIntosh BR. Running Economy from a Muscle Energetics Perspective. *Front Physiol*. 2017;8:433. doi:10.3389/fphys.2017.00433

[61] Srivastava S, Patten C, Kautz SA. Altered muscle activation patterns (AMAP): an analytical tool to compare muscle activity patterns of hemiparetic gait with a normative profile. *J Neuroeng Rehabilitation*. 2019;16(1):21. doi:10.1186/s12984-019-0487-y

1 Figure legends

2 **Figure 1 Behavioural results and medication related changes in STN LFPs in different movement**
3 **states**. A boxplot of the standard deviation of the patients' stepping frequency is presented in **A** while
4 the patients' stepping frequency is depicted in **B** (where BS is borderline significant). The amplitude
5 spectral density (ASD) of activity in the STN over the sitting, standing and stepping trials is presented
6 in **C**, **D, and E** respectively, where the shaded area is the 25th – 75th percentile. The box plots **below**
7 **C**, **D, and E** demonstrate the group median, 5th, 25th, 75th, and 95th percentile, as well as the data for
8 each participant (for each STN), for the significant cluster.

9

10 **Figure 2 STN activity by movement and medication status.** A boxplot displaying amplitude
11 spectral density (ASD) for resting, standing, and stepping, averaged over medication status is
12 displayed in **A** for low-beta, and **B** for high-beta. The medication status (ON vs. OFF) averaged over
13 the movement status (resting, standing, stepping) is presented in **C** for low-beta, and **D** for high-beta.

14

15 **Figure 3 Analysis of electrophysiology by stepping phase**. The normalized force of the plates by
16 the stepping phase, computed using the Hilbert transform, is depicted in **A**. The time frequency
17 decompositions of the STN, gastrocnemius, and peroneus longus OFF medication are displayed in
18 **D**, **H**, and **L**, while ON medication items are displayed in **E**, **I**, and **M** respectively. Data are normalized
19 within condition, i.e. separate normalization for each condition. **B**, **F**, and **G** depict the beta activity
20 averaged over 12-35 Hz (**B**), 25-30 Hz (**F**), and 12-15 Hz (**G**), for OFF and ON medication, while the *t*-

21 test scores between OFF and ON in the time frequency domain in the STN, gastrocnemius, and
22 peroneus longus are shown in **C**, **K**, and **O** respectively. The *t*-test scores between OFF and ON from
23 1-100 Hz are presented in **J** for the gastrocnemius, and **N** for the peroneus longus. Statistically
24 significant clusters are outlined in **K** and **O** for gastrocnemius (*p* = .030) and peroneus longus (*p* =
25 .043), respectively.

26

27 **Figure 4 Intermuscular and STN-EMG coherence by stepping phase.** Intermuscular coherence
28 (IMC) by stepping phase between the gastrocnemius and peroneus longus muscles of the same leg
29 is presented in **A**, **B**, and **C**. STN-Gastrocnemius coherence by stepping phase is presented in **D** and
30 **E,** with STN-Peroneus Longus coherence presented in **F** and **G**. Time frequency maps are presented
31 for OFF medication in **B, D,** and **F,** and ON medication in **C, E,** and **G**. The difference between OFF
32 and ON medication for IMC (based on the *t*-test score) is presented in **A**, and statistically significant
33 clusters are outlined in black (*p* = .020). For **B**, **C**, **D**, **E**, **F**, and **G**, the coherence difference is
34 computed by first calculating the phase locked coherence and then subtracting a permuted version

1 where the phase locked coherence is recalculated but with permuted EMG signal (for IMC only one
2 of the signals is permuted).

3

4 **Figure 5 Effect of STN beta bursts from phases 0 to π/4.** Beta bursting activity is extracted where
5 the amplitude exceeds the 75th percentile (indicated by the vertical red line in the figures), shown for
6 OFF medication in **A** and ON medication in **B**. The concomitant activity is selected for the
7 gastrocnemius and peroneus longus, with the *t*-test score between OFF medication and ON
8 medication computed and presented in **C** and **D**. Statistically significant clusters are outlined in
9 black for gastrocnemius (*p* = .020) and peroneus longus (*p* = .040).

10

11 **Table 1 Patient data**

Patient ID	DBS Leads	Target	DH	M/F	Age	Dis. Dur (Yrs)	Predominant Symptoms Before Surgery	Excluded Data: ON (%)	Excluded Data: OFF (%)
P001	Medtronic SenSight (directional)	STN	R	F	63	9	Akinetic-rigid	0.98	0.48
P002	Medtronic SenSight (directional, Percept)	STN	L	M	75	6	Tremor both hands, light rigidity	6.43	4.31
P003	Medtronic SenSight (directional)	STN	R	M	61	5	Tremor, worst on right side	12.23	7.22
P004	Medtronic SenSight (directional)	STN	-	M	58	12	Rigidity and bradykinesia	4.21	1.80
P005	Boston Scientific (directional)	STN	R	M	66	10	Akinetic-rigid	5.68	2.64
P006	Medtronic SenSight (directional)	STN	R	M	57	5	Tremor dominant worst on right, bradykinesia and FOG	3.59	4.51
P007	Boston Scientific (directional)	STN	R	M	63	13	Akinetic-rigid	85.92	84.75
P008	Boston Scientific Octrode (non-directional, 2201 leads)	Vim/Vop + STN	R	M	70	9	Tremor dominant	23.51	30.07
P009	Medtronic SenSight (directional, 33005 leads)	STN	R	F	62	12	Akinetic-rigid	10.88	11.44
P010	Boston Scientific (directional)	STN	R	M	69	30	Tremor dominant	6.82	18.49
P011	Medtronic SenSight (directional)	STN	R	F	67	12	Severe off symptoms with dyskinesia and rigidity, some right-side tremor	0.21	3.37
P012	Medtronic SenSight (directional)	STN	R	M	67	6	Tremor and rigidity in left side	13.58	7.21
P013	Boston Scientific (directional)	STN	R	M	61	14	Tremor dominant	23.92	42.06
P014	Medtronic SenSight (directional)	STN	-	F	68	7	Rigidity in left side	1.14	0.90

12 Firstly, patient ID is given, along with the type of deep brain stimulation (DBS) leads, and the surgical target. The patients' dominant hand (DH)
13 is also shown, as is their sex assigned at birth (M/F), age, disease duration (Dis. Dur), and predominant symptoms before surgery.
14

1 **Table 2 Patient data continued**

Patient ID	Medication Levodopa Equivalent Daily Dose		UPDRS-III		Bipolar Recording Configuration		Chronic Stimulation Configuration		Freezer
	Before Ext.	During Ext.	ON Med.	OFF Med.	Left	Right	Left	Right	
P001	1260 mg	Same	12	52	3–6	11–14	1.9 mA, case +, 4 −, 5 −, 6 −	1.6 mA, case +, 9 −, 10 −, 11 −	No
P002	800 mg	Same	49	51	1–2	9–10	2.5 mA, case +, 0 −	3.0 mA, case +, 8 −	No
P003	1150 mg	Same	11	22	4–7	14–15	3.8 V, case +, 1 −	2.1 V, case +, 9 −	No
P004	1555 mg	Same	10	47	2–5	13–15	3.8 V, case +, 1 −	3.8 V, case +, 10 −	No
P005	900 mg	Same	47	67	3–6	8–11	3.6 mA, (case +, 3 −) or 3.1 mA (case +, 0 −)	1.9 mA, case +, 9 −	Yes
P006	1230 mg	Same	12	67	1–4	13–15	3.0 V, case +, 0 −	2.8 V, case +, 11 −	No
P007	1100 mg	900 mg	29	43	6–7	9–12	2.0 mA, case +, 4 − (10%), 1 − (90%)	2.8 mA, case +, 12 − (20%), 10 − (80%)	Yes
P008	400 mg	Same	15	21	4–5	9–10	4.1 mA, case + 16%, 0 − 40%, 1 + 2%, 2 + 13%, 3 − 45%, 4 − 14%, 5 + 8%, 6 − 1%, 7 + 1%	4.6 mA, case + 89%, 8 − 57%, 9 + 6%, 10 + 2%, 11 − 5%, 12 − 38%, 13 + 3%	No
P009	740 mg	Same	6	31	0–1	8–10	2.9 mA, 1 − (1.0), 0 − (1.0), case +	2.0 mA, 11 +, 12 −, 13 −, 14 −	No
P010	700 mg	Same	31	37	0–1	8–9	2.3 mA, case +, 0 −	0.6 mA, case +, 10 − (25%), 9 − (25%), 8 − (50%)	No
P011	1103 mg	Same	9	57	1–4	12–15	0.6 mA, case +, 2 −	0.6 mA, case +, 10 −	No
P012	475 mg	Same	30	24	1–4	11–14	1.6 mA, case +, 4 − (0.6 mA), 5 − (0.6 mA), 3 − (0.4 mA)	2.7 mA, case +, 13 − (0.6 mA), 14 − (1.5 mA), 15 − (0.6 mA)	No
P013	980 mg	Same	17	45	2–5	9–12	2.2 mA, case +, 4 − (23%), 5 − (54%), 6 − (23%)	1.5 mA, case +, 12A − (31%), 13 − (46%), 14 − (23%)	Yes
P014	745 mg	Same	17	24	2–5	12–15	0.5 mA, case +, 2 −	0.5 mA, case +, 10 −	Yes

2 Medication before and after externalisation is reported, along with the Unified Parkinson's Disease Rating Scale part III (UPDRS-III) both ON and
3 OFF medication. The bipolar configuration used for the analysis, as well as the configuration for chronic stimulation, are reported. Contacts are
4 numbered from 0 on the left hemisphere and from 8 on the right. For directional leads, contacts 1-3 (left) and 9-11 (right) correspond to the
5 directional contacts on the second-lowest level. In addition, whether the patient is a freezer or not is also included in the table. Pat.=patient;
6 Ext.=externalisation; Med.=medication.
7
8

Figure 1
420x303 mm (x DPI)

Resting, Standing, and Stepping STN Activity

ON and OFF Medication STN Activity

A Low Beta

B High Beta

C Low Beta

D High Beta

Movement Status

Medication Status

ASD

ASD

1

2

*Figure 2*

3

328x140 mm (x DPI)

4

Figure 3
559x408 mm (x DPI)

Figure 4
492x242 mm (x DPI)

Figure 5
270x235 mm (x DPI)